Duffy Sean P. sold $509K of OMDA
Duffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
Omada Health, Inc.
No enriched coverage for $OMDA in the last 7 days.
Duffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
Omada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.
Duffy Sean P. (Chief Executive Officer) sold 21,570 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($20.90–$24.81, $0.51M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.
Recent OMDA coverage spans insider activity, earnings and financial news.
In the last 30 days, OMDA insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($1.5M). The most active reporter was Duffy Sean P., Chief Executive Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal weak confidence, modest negative pressure on the stock.
Raised guidance and record margins suggest improving unit economics and profitability trajectory, but management flagged H2 growth moderation and potential GLP-1 coverage pullbacks.
The filing is a routine insider-sale disclosure, not a new operating or financial catalyst, but it can modestly affect near-term sentiment.
The article provides fresh operating detail (record Q2 framing, member economics, and channel expansion) that can support a near-term re-rating of growth and margin trajectory.
Omada Health, which went public in June, said Wei-Li Shao will become CEO on Jan. 1, replacing founder Sean Duffy, who will move to executive chair. The change was announced with Q2 results. Omada reported Q2 revenue of $88 million (+43% Y/Y), profit of $5 million, gross margin of 73%, and raised 2026 revenue guidance to $334 million-$340 million.
alphai scores every news story that mentions OMDA with an AI model for sentiment and relevance, and aggregates insider trades from Omada Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Duffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readOmada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.
6 min readDuffy Sean P. (Chief Executive Officer) sold 21,570 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($20.90–$24.81, $0.51M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readOmada Health (NASDAQ:OMDA) reported record Q2 performance, with growth driven by demand for GLP-1-related programs and broader diabetes and hypertension offerings, according to CEO Cook. Trailing 12-month revenue per member rose 2% to $284. Omada targets 20%+ revenue growth and 70%+ gross margin, and is expanding with CVS, Optum and HCSC.
6 min readOmada Health, which went public in June, said Wei-Li Shao will become CEO on Jan. 1, replacing founder Sean Duffy, who will move to executive chair. The change was announced with Q2 results. Omada reported Q2 revenue of $88 million (+43% Y/Y), profit of $5 million, gross margin of 73%, and raised 2026 revenue guidance to $334 million-$340 million.
4 min readOmada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch
6 min readCook Steven L. (Chief Financial Officer) sold 35,600 shares of Omada Health, Inc. (OMDA) at an average of $22.87 ($22.76–$23.09, $0.81M total) across 2 trades over 2026-07-01 to 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readDuffy Sean P. (Chief Executive Officer) sold 25,886 shares of Omada Health, Inc. (OMDA) at an average of $22.68 ($22.67–$22.70, $0.59M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min readOmada Health (OMDA) said CEO Sean P. Duffy sold 17,258 shares in open-market trades from June 24–26, 2026, per an SEC Form 4. The weighted-average sale price was $19.82/share, cutting his beneficial ownership from 0.6928% to 0.6638% (1,246,262 shares total). Sales were under a 10b5-1 plan adopted March 13, 2026.
4 min readCook Steven L. (Chief Financial Officer) sold 50,950 shares of Omada Health, Inc. (OMDA) at an average of $20.31 ($19.89–$21.07, $1.03M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
2 min read